Release Date: August 30, 2019
Expiration Date: August 30, 2020
Estimated time to complete: 45 minutes
This educational activity is jointly provided by AXIS Medical Education and
the Association of Community Cancer Centers (ACCC).
This activity is supported in part by educational grants from Astellas and Seattle Genetics, Amgen, Celgene Corporation, Daiichi Sankyo, Inc., Lilly, Merck & Co., Inc. and TESARO, Inc.
The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.
ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.
At the end of this educational activity, participants should be able to:
Philip Agop Philip, MD, PhD, FRCP
Kathryn Cramer Endowed Chair in Cancer Research
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Pharmacists
This knowledge-based activity is approved for 0.75 contact hours of continuing pharmacy education credit. JA4008106-9999-19-039-H01-P
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.75 contact hours.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
AXIS Contact Information
For information about the accreditation of this program please contact AXIS at firstname.lastname@example.org.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Advisor: AbbVie Inc.; Caris Diagnostics Inc.; Celgene Corporation; Eisai Inc.; Halozyme Inc.; Ipsen Biopharmaceutical Inc.; Lexicon Pharmaceuticals Inc.; Lilly USA; Merck & Co, Inc.; Novartis Pharmaceuticals Corp; Rafael Pharmaceuticals Inc.; Taiho Oncology Inc; Biolinx; Forty Seven Inc. Consultant: AbbVie Inc.; Celgene Corporation; Lilly USA; Merck & Co, Inc.; Rafael Pharmaceuticals Inc Contracted Research: AAA Pharmaceutical Inc.; Astellas Pharma Global Development Inc.; Boston Biomedical Pharma Inc.; Bristol-Myers Squibb Co.; Celgene Corporation; Daiichi Sankyo Inc.; Eisai Inc.; Gilead Sciences Inc.; Halozyme Inc.; Incyte Corporation; Lilly USA; Merck & Co, Inc.; Novocure; QED Therapeutics; Taiho Oncology Inc.; Biolinx; Thyme; Bayer Pharmaceuticals Corp; Forty Seven Inc. Data and Safety Monitoring Board: ASLAN Pharmaceuticals; Blueprint Medicines; Erytech Pharma SA; Lexicon Pharmaceuticals Inc. Serve(d) as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Co.; Celgene Corporation; Ipsen Biopharmaceutical Inc.; Merck & Co, Inc.
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation and Request for Credit
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.